The study performed by Badar et al. indicated that the acquisition of detectable levels of RAS and/or FLT3-ITD gene mutation at the moment of MDS transformation to AML resulted in approximately 30% of cases and predicted extremely poor outcomes [24]. This evidence concerns the gene FLT3 and acute myeloid leukemia.